2019
Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation
Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. Journal Of Neuro-Oncology 2019, 144: 553-562. PMID: 31377920, PMCID: PMC7392129, DOI: 10.1007/s11060-019-03257-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCognitionCombined Modality TherapyCranial IrradiationFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansInduction ChemotherapyLongitudinal StudiesLymphomaMaleMiddle AgedPrognosisQuality of LifeSurvival RateTransplantation, AutologousYoung AdultConceptsWhole brain radiotherapyReduced-dose whole-brain radiotherapyPrimary central nervous system lymphomaHDC-ASCTCortical atrophyAttention/executive functionPCNSL patientsAutologous stem cell transplantConsolidation whole-brain radiotherapyAutologous stem cell transplantationCentral nervous system lymphomaCognitive functionIntroductionThe standard treatmentLongitudinal cognitive assessmentsProgression-free patientsHigh-dose chemotherapyMethotrexate-based chemotherapyLong-term remissionPrimary CNS lymphomaNervous system lymphomaStem cell transplantStem cell transplantationBrain structure abnormalitiesPost-induction chemotherapyWhite matter disease
2012
A prognostic gene expression signature in infratentorial ependymoma
Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, Ledoux A, Wilson C, Long L, Gilbert MR, Aldape K, For the Collaborative Ependymoma Research Network. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathologica 2012, 123: 727-738. PMID: 22322993, PMCID: PMC4013829, DOI: 10.1007/s00401-012-0941-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAntigens, NeoplasmChildCluster AnalysisDatabases, GeneticDNA Topoisomerases, Type IIDNA-Binding ProteinsEpendymomaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInfratentorial NeoplasmsLongitudinal StudiesMaleOligonucleotide Array Sequence AnalysisPrognosisReproducibility of ResultsSex FactorsSurvival AnalysisYoung AdultConceptsRecurrence-free survivalInfratentorial ependymomaClinical outcomesReal-time reverse transcriptase-polymerase chain reaction assaysReverse transcriptase-polymerase chain reaction assaysGroup 1 tumorsPrognostic gene expression signaturesTranscriptase-polymerase chain reaction assaysGroup 2 tumorsGene expression subgroupsPolymerase chain reaction assaysClinical factorsGene expression signaturesIndependent predictorsPrognostic significanceInfratentorial compartmentHistological factorsClinical behaviorChain reaction assaysClinical aggressivenessPrognostic signatureExpression subgroupsEpendymomaMolecular alterationsMultivariate analysis